Veristat has launched its Clinical Trial, Biostatistics and Programming operations in Taipei, Taiwan with the opening of a new office.
The expansion of operations into Taiwan is aimed at supporting growing client demand for clinical trial, biostatistics and programming excellence in the region.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Veristat CEO Patrick Flanagan said: “The growth of Veristat’s operations in Taiwan is a critical next step in supporting our clients looking to prepare their clinical trial data for marketing applications worldwide.
“We have strategically selected Taipei, Taiwan, as our entry into Asia because the location complements our core values and culture of partnership, respect, innovation, and agility.
“We are building a highly-experienced team of statistical programmers and clinical trial professionals in our new Taipei office to better serve our clients and their increasing requests for local and international regulatory submission support.”
The company plans to host the opening celebration of the new office on 02 September of this year.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataVeristat Taipei operations director Philip Ho said: “Establishing a footprint in Taipei allows local Veristat programmers to support the fast-growing clinical development market in Taiwan. My team is growing to support submission programs for both local sponsors, as well as our North American sponsors.”
Based in the US, Veristat is a clinical research organization (CRO) and partners with pharmaceutical, biotechnology, and medical device firms to advance their therapies from clinical development stage to regulatory submission process.
The company has strategic experience in decision-making and biometrics expertise to collect, audit and report clinical trial data to various regulatory agencies.
